InstaCare Corp. the exclusive distributor of the Shasta Genstrip diagnostic testing strips, a leading provider of prescription and non-prescription diagnostics, home testing products for the chronically ill, as well as leading fulfilment provider of direct to patient diabetes programmes, and a developer of revolutionary cell phone centric e-health products and technologies, announced that the company's board of directors will, during the month of January 2011, release Guidance for fiscal year 2011. On January 10, 2011, a preliminary Guidance release will highlight financial information related to its new at-home diagnostic product, the Shasta Genstrip.

A more comprehensive Guidance release will be issued on January 24, 2011. A shareholder conference call is also planned following the January 24 Guidance release.

Robert Jagunich, chairman of InstaCare Corp., noted enthusiastically, “These Guidance releases, to be evaluated by an independent financial analyst prior to their release, should communicate the basis of our internal optimism and our confidence in InstaCare's business and revenue models. We believe that our shareholders and the investment community will be impressed with our financial and marketing plan for 2011 and our strategic long term vision. InstaCare will be forecasting, for the first time, the depth and breadth of the financial opportunity that is represented by our new at-home diagnostic testing product, Shasta Genstrip.”